Aclaris Therapeutics (ACRS) Non-Current Assets (2014 - 2026)

Aclaris Therapeutics' Non-Current Assets history runs 13 years deep, the most recent figure standing at $88.5 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 0.91% year-over-year to $88.5 million; the TTM figure through Mar 2026 stood at $312.5 million (up 12.75% YoY), while the FY2025 annual figure was $64.1 million, down 32.03% from the prior year.
• Non-Current Assets was $88.5 million for Q1 2026 at Aclaris Therapeutics, up from $64.1 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $102.7 million in Q2 2023 to a low of $11.1 million in Q3 2022.
• Historically, Non-Current Assets has averaged $60.5 million across 5 years, with a median of $64.1 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets tumbled 80.84% in 2022, then surged 761.61% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $23.0 million in 2022, then jumped by 197.44% to $68.5 million in 2023, then soared by 37.68% to $94.4 million in 2024, then slumped by 32.03% to $64.1 million in 2025, then jumped by 37.96% to $88.5 million in 2026.
• The last three Non-Current Assets figures came in at $88.5 million (Q1 2026), $64.1 million (Q4 2025), and $74.9 million (Q3 2025), per Business Quant data.